Vitaz — Clinical Trial Site

117 Registered trials

48 Currently recruiting

Organisation

Vitaz

Location

Sint-Niklaas, Belgium

Identifier

ORG-100041146

Address

Moerlandstraat 1, 9100, Belgium

Departments

#1002: medical oncology
032008: Medische Oncologie
056011: Medische Oncologie
4202 : Pneumology
BE10002:Gastro-enterologie
BE10005: Gastro-entérologie
Cardiology
Departement of Hematology
Department of Oncology
Department of Urology
Diabetology-Endocrinology
Dienst longziekten
Division of Pulmonary and Infectious Diseases
Endocrinology
Gastro Enterology
Gastro-enterologie
Gastro-enterology
Gastroenterology
Gastroenterology - Hepatology
Gastrogroep
Haematology
Hematologie
Hematology
Internal diseases
Longziekten
Medical Oncology
Medical Oncology/Hematology
Medische oncologie
n/a
NA
Neurology
Nierziekten & Dialyse
Oncologie
Oncology
Palliative care
Pneumologie
pneumology
Psychiatry
Pulmonary
Pulmonary and Infectious Disease
Pulmonary and Infectious Diseases
Pulmonary diseases department
Pulmonology
Thoracic oncology
Urology

Clinical trials at this site (117)

Search interface

A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B… Recruiting

2022-503114-23-00 Breast Cancer 3 2023-12-19
Semaglutide for the treatment of glucose intolerance in women with prior gestational diabetes Recruiting

2022-502082-22-00 prediabetes 11 2023-09-14
Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting

2022-502703-30-00 neuroendocrine tumours 6 2023-06-28
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into platinum/pemetrexed-based first-line treatment for epithelioid m… Recruiting

2024-515293-27-00 Malignant pleural mesothelioma, epithelioid subtype (st 4 2023-02-24
Prevention of postoperative endoscopic disease recurrence in Crohn’s disease: a multicentric study that compares the systematic start of bio… Recruiting

2022-500311-39-00 Patients with Crohn's disease undergoing surgery and ha 6 2022-09-08
A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL/SLL Recruiting

2023-507699-38-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2022-08-30
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials (MMRd-GREEN) Recruiting

2023-503267-42-00 Patients with a histological diagnosis of mismatch- rep 5 2022-06-10
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting

2023-506857-40-00 Prostate Cancer 5 2019-01-08
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Part… Ended

2023-506146-23-00 Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the 4 2025-11-17
BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part… Ended

2024-515740-23-00 Extensive-Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-03-25
Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN) Ended

2024-515538-34-00 Head and Neck Squamous Cell Carcinoma 10 2025-02-27
Controlled Interruption of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Infections Ended

2024-511016-25-00 Chronic hepatitis B infection 4 2025-01-15
Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn’s Disease Patients Ended

2023-504040-34-01 Crohn’s Disease 5 2024-11-12
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive… Ended

2024-510908-37-00 KRAS G12C-Positive Advanced or Metastatic Non-Small Cel 5 2024-08-28
Subcutaneous infliximab after a previous intravenous dose optimization (AMARETTO trial) Ended

2023-508166-15-00 Ulcerative colitis (UC), Inflammatory bowel disease typ 6 2024-04-29
Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended

2023-503231-17-00 Unresectable Pleural Mesothelioma 5 2024-04-26
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-… Ended

2022-502446-27-00 Relapsed or Refractory Myeloma 5 2024-02-26
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended

2022-502669-14-00 Small cell lung cancer (SCLC) 5 2023-12-18
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended

2022-500802-16-00 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non- 5 2023-11-01
A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com… Ended

2022-501576-25-00 Melanoma 5 2023-07-07
Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended

2022-502145-10-00 Hormone Receptor (HR)-Positive, Human Epidermal Growth 5 2023-06-06
A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung c… Ended

2024-511169-12-00 Non-Small Cell Lung Cancer 5 2023-03-28
Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended

2023-507187-39-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2023-03-23